INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of INmune Bio (NASDAQ:INMB) from a sell rating to a hold rating in a report released on Sunday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of INmune Bio in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $18.00.

INmune Bio Trading Down 6.1%

NASDAQ:INMB opened at $2.01 on Friday. INmune Bio has a 12-month low of $1.38 and a 12-month high of $11.64. The firm has a market cap of $53.43 million, a price-to-earnings ratio of -0.95 and a beta of 0.91. The company’s 50-day moving average is $1.77 and its two-hundred day moving average is $2.87.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.07. On average, equities research analysts forecast that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Trading of INmune Bio

A number of large investors have recently made changes to their positions in INMB. XTX Topco Ltd raised its holdings in INmune Bio by 240.9% during the 2nd quarter. XTX Topco Ltd now owns 125,847 shares of the company’s stock valued at $291,000 after buying an additional 88,928 shares during the period. Westside Investment Management Inc. raised its position in INmune Bio by 384.0% during the 3rd quarter. Westside Investment Management Inc. now owns 103,450 shares of the company’s stock valued at $214,000 after purchasing an additional 82,075 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of INmune Bio by 1,042.7% in the second quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock valued at $169,000 after acquiring an additional 66,700 shares in the last quarter. PNC Financial Services Group Inc. bought a new stake in shares of INmune Bio in the second quarter valued at about $87,000. Finally, Focus Partners Advisor Solutions LLC grew its holdings in INmune Bio by 321.2% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 48,813 shares of the company’s stock worth $113,000 after acquiring an additional 37,224 shares in the last quarter. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.